Dose Frequency RCT on DTTC in Children With CAS
Childhood Apraxia of Speech
About this trial
This is an interventional treatment trial for Childhood Apraxia of Speech focused on measuring treatment, dose frequency, speech sound disorders, cumulative dosage, whole word accuracy, Dynamic Temporal and Tactile Cueing, DTTC, Childhood apraxia of speech
Eligibility Criteria
Inclusion Criteria: CAS diagnosis confirmed by research team as described below (e.g., Iuzzini-Seigel et al., 2022; Shriberg et al., 2017; Strand & McCauley, 2019), 2;6-7;11 years of age at treatment commencement; English as the primary language; Exclusion Criteria: concomitant developmental disorders (including autism, global developmental delay, intellectual disability); diagnosis of severe or primary dysarthria as described below; palatal or structural orofacial anomalies as described below, uncorrected vision impairment hearing loss; receiving speech treatment elsewhere over the course of this study, although language, augmentative and alternative communication treatment, or similar non-speech treatment, would be permitted Receptive Language Index standard score less than 70 on the Receptive-Expressive Emergent Language Test, 4th edition (REEL-4; Brown et al., 2020) for children 2-3 years of age, the Clinical Evaluation of Language Fundamentals - Preschool 3rd edition (CELF-P3; Wiig et al., 2020) for children 4-5 years of age, or the Clinical Evaluation of Language Fundamentals - 5th edition (CELF-5; Wiig et al., 2013) for children 6-7 years of age, Nonverbal Index standard score less than 70 on the Reynolds Intellectual Assessment Scales- 2nd edition, Remote (Reynolds & Kamphaus, 2015), and no evidence of communicative intent, attempts at verbal communication, focused attention to the clinician's face, or demonstrated ability to imitate during the DEMSS.
Sites / Locations
- Marquette URecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
High Dose Frequency
Low Dose Frequency
This group will receive treatment 4x/week for 6 weeks
This group will receive treatment 2x/week for 12 weeks